Heather CPA - Provectus Biopharmaceutica Chief Officer

Summary

PVCTDelisted Stock

USD 0.11 0.00 0.00%

Insider

Heather CPA is Chief Officer of Provectus Biopharmaceuticals

Age	56
Phone	866 594 5999
Web	https://www.provectusbio.com

Provectus Biopharmaceutica Management Efficiency

The company has return on total asset (ROA) of (1.8529) % which means that it has lost $1.8529 on every $100 spent on assets. This is way below average. Provectus Biopharmaceutica's management efficiency ratios could be used to measure how well Provectus Biopharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.

Compare Provectus Biopharmaceutica to Peers

Provectus Biopharmaceuticals currently holds 2.29 M in liabilities with Debt to Equity (D/E) ratio of 0.25, which may suggest the company is not taking enough advantage from borrowing. Provectus Biopharmaceutica has a current ratio of 0.26, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Provectus Biopharmaceutica until it has trouble settling it off, either with new capital or with free cash flow. So, Provectus Biopharmaceutica's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Provectus Biopharmaceutica sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Provectus to invest in growth at high rates of return. When we think about Provectus Biopharmaceutica's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives			INSIDER Age
	Shane Williams	Century Therapeutics	N/A
	Adriana MBA	Crinetics Pharmaceuticals	N/A
	CPA CPA	Acurx Pharmaceuticals LLC	58
	MBA MR	Aerovate Therapeutics	62
	Brian McAlister	NervGen Pharma Corp	N/A
	Yvonne MBA	Nkarta Inc	64
	George Eldridge	Aerovate Therapeutics	62
	Michelle Zhang	Ikena Oncology	N/A
	Harold DMD	NervGen Pharma Corp	N/A
	Prof Schlessinger	Celldex Therapeutics	80
	Martin MD	Xilio Development	63
	Noreen MD	Kezar Life Sciences	59
	William BASc	NervGen Pharma Corp	60
	Kenneth JD	Century Therapeutics	N/A
	Evan Hecker	Ikena Oncology	N/A
	BCPS PharmD	Xilio Development	47
	Robert Westwood	Cyclacel Pharmaceuticals	80
	Robert DeLuccia	Acurx Pharmaceuticals LLC	79
	Anthony MBA	Celldex Therapeutics	63
	MBA MD	Scholar Rock Holding	57
	Michael Diem	Century Therapeutics	53

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. Provectus Biopharmaceuticals, Inc. was incorporated in 2002 and is based in Knoxville, Tennessee. Provectus Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 4 people. Provectus Biopharmaceuticals [PVCT] is traded as part of a regulated electronic over-the-counter service offered by the NASD. Provectus Biopharmaceutica is listed under Pharmaceutical Products category by Fama And French industry classification.

Management Performance

Return On Asset

-1.85

Provectus Biopharmaceutica Management Team

Elected by the shareholders, the Provectus Biopharmaceutica's board of directors comprises two types of representatives: Provectus Biopharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Provectus. The board's role is to monitor Provectus Biopharmaceutica's management team and ensure that shareholders' interests are well served. Provectus Biopharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Provectus Biopharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.

	Heather CPA, Chief Officer
	Bruce Horowitz, COO Director
	Eric Wachter, CTO and Executive VP

Provectus Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Provectus Biopharmaceutica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Asset	-1.85
	Operating Margin	(4.77) %
	Current Valuation	46.73 M
	Shares Outstanding	419.55 M
	Shares Owned By Insiders	3.69 %
	Shares Owned By Institutions	0.04 %
	Number Of Shares Shorted	1.82 M
	Price To Earning	(0.48) X
	Price To Book	5.44 X
	Price To Sales	55.94 X

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

Note that the Provectus Biopharmaceutica information on this page should be used as a complementary analysis to other Provectus Biopharmaceutica's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Other Consideration for investing in Provectus OTC Stock

If you are still planning to invest in Provectus Biopharmaceutica check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Provectus Biopharmaceutica's history and understand the potential risks before investing.

	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC